NCT01063101已完成1 期
A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers
Baxalta now part of Shire2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年1月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Change in peak thrombin concentration from baseline as measured by the Thrombin Generation Assay (TGA).
研究概览
简要总结
The purpose of the study is to investigate whether orally administered BAX 513 (different doses administered for 5 days) affects hemostatic parameters in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is >= 18 and < 70 years old at the time of screening
- •Is able to provide signed and dated informed consent
- •Is a healthy male or female adult
- •If female and of childbearing potential, subject demonstrates a negative serum pregnancy test, and agrees to employ adequate birth control measures; (e.g., oral contraceptives, barrier method) for the duration of the study
- •If female and receiving hormone replacement therapy (HRT), subject agrees to abstain from HRT for the duration of the study
- •Subject's medical history and physical exam are normal
- •Subject's lab values for complete blood count (CBC) and clinical chemistry are within normal ranges
- •Is able to comprehend and comply with all aspects of the protocol and signed informed consent
排除标准
- •If female, subject is pregnant or lactating at the time of study enrollment
- •Has participated in another clinical study involving an investigational product (IP) or device within 30 days of screening or is scheduled to participate in another clinical study involving an IP or device during the course of this study
- •Has a history of drug allergy in general or hypersensitivity to fucoidan containing products/foods or seafoods
- •Medical and/or family history of thrombophilic tendencies, eg Protein C or S-deficiency, ATIII deficiency, FV Leiden mutation, Prothrombin 20210A mutation, lupus type inhibitor, antiphospholipid antibodies
- •Medical history or clinical findings of a significant bleeding disorder
- •Medical history of thrombotic events such as venous thromboembolism (VTE), myocardial infarction (MI), stroke or transient ischemic attack (TIA)
- •Any other clinically relevant history of disease, eg malabsorption disorders, malignancies
- •Any clinically significant abnormal laboratory values or abnormal ECG findings that in the opinion of the investigator are considered clinically relevant
- •Seropositivity for HBs-Ag, HCV, HIV-1 or HIV-2 antibodies
- •Symptoms of a clinically relevant illness within 3 weeks before screening
- •A history of, or suspected, drug or alcohol abuse, or subject tests positive on a Drugs of Abuse screen within 1 week of dosing
- •Intake of IP or related (fucoidan-containing) product within 1 week prior to study enrollment
- •Any planned surgical or dental procedure during the course of this study
- •Any recent surgery within 30 days of enrollment
- •Presence of signs or symptoms consistent with an infection, such as fever, chills, or nausea during screening in this study
- •Chronic or regular use of aspirin, ibuprofen, coumarin derivatives, antiplatelet drugs, within 1 week before enrollment
- •Use of concomitant drugs diclofenac or [paracetamol if > 2 g/day] within 1 week before first day of study dosing
- •Plasmapheresis or platelet donation within 3 weeks of screening and until final visit
- •Any medical condition that may compromise the ability to give written informed consent or to comply with the study protocol
- •Subject is a member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study
结局指标
主要结局
Change in peak thrombin concentration from baseline as measured by the Thrombin Generation Assay (TGA).
时间窗: 7 months (= anticipated study duration)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02448810Baxalta now part of Shire115
招募中
1 期
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid TumorsRefractory Solid TumorsNCT05150457Binacea Pharma, Inc.48
已完成
1 期
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid TumorsSolid TumorsNCT00586092Herbert Hurwitz45
已完成
1 期
Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453HypertensionChronic Heart FailureNCT02845037Bial - Portela C S.A.80
已完成
1 期
Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsHealthyNCT02175394Boehringer Ingelheim18